# US 2010/0063064 A1 · Substituted Triazole Derivatives As Oxytocin Antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063064 A1
- Document ID: US20100063064A1
- Status: Published application
- Kind: A1
- Application number: 12/621,927
- Filed: 2009-11-19
- Published: 2010-03-11
- Earliest claimed: 2003-09-22
- Assignees: Pfizer Inc.
- Inventors: Alan Daniel Brown; David Ellis; Christopher Ronald Smith
- Web page: https://patentgrep.com/patent/US20100063064A1

## CPC

- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/12: for climacteric disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).

## Claims

### Claim 1

A compound of formula (I)
wherein
X and Y are each N;
V and W are each C—R6;
Z is C—H or N;
R1 is selected from:
(i) a phenyl ring substituted with two or more substituents, which may be the same or different, each independently selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, C(O)NR7R8, NR7R8, NR7C(O)R10 and N[C(O)R10]2; and
(ii) a five to seven membered aromatic heterocyclic ring containing 1-3 hetero atoms selected from N, O and S and N-oxides thereof; said ring being optionally substituted with two or more substituents, which may be the same or different, selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, C(O)NR7R8, NR7R8, NR7C(O)R10 and N[C(O)R10]2;
R2 is selected from:
(i) H, OH, OR9, NR7R8, NR7C(O)R10 and N[C(O)R10]2;
(ii) a 5-7 membered N-linked heterocycle containing 1-3 heteroatoms selected from N, O and S; said ring being optionally substituted with one or more groups selected from (C1-C6)alkyl, (C1-C6)alkoxy and C(O)NR7R8; and
(iii) (C1-C6)alkyl optionally substituted with an N-linked 5-7 membered heterocycle containing 1-3 heteroatoms selected from N, O and S;
R3 is selected from H and (C1-C6)alkyl;
R4 is selected from H, (C1-C6)alkyl and OR9;
R5 is selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, NR7R8, NR7C(O)R10 and N[C(O)R10]2;
R6 is selected from H, halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, NR7R8, NR7C(O)R10, N[C(O)R10]2 and C(O)NR7R8;
R7 and R8, which may be the same or different, are selected from H and (C1-C6)alkyl;
R9 is (C1-C6)alkyl, which is optionally substituted with one or more groups each independently selected from (C1-C6)alkoxy and an N-linked 5-7 membered heterocycle containing 1-3 heteroatoms selected from N, O and S; and
R10 is selected from (C1-C6)alkyl and (C1-C6)alkoxy;
or a pharmaceutically acceptable salt;
thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound according to claim 1 wherein V and W are each CH; or a pharmaceutically acceptable salt thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound according to claim 1 wherein Z is N; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1 wherein Z is CH; or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1 wherein R1 is selected from:
(i) a phenyl ring substituted with two substituents, which may be the same or different, each independently selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, C(O)NR7R8, NR7R8, NR7C(O)R10 and N[C(O)R10]2; and
(ii) a pyridyl ring or N-oxide thereof each substituted with two substituents, which may be the same or different, each independently selected from halo, (C1-C6)alkyl, (C1-C6)alkoxy, cyano, C(O)NR7R8, NR7R8, NR7C(O)R10 and N[C(O)R10]2; or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The compound according to claim 7 wherein R1 is a phenyl ring substituted with two substituents, which may be the same or different, each independently selected from fluoro, chloro, methyl, methoxy and cyano; or a pharmaceutically acceptable salt thereof.

### Claim 9

(canceled)

### Claim 10 (depends on 7)

The compound according to claim 7 wherein R2 is selected from:
(i) H, (C1-C3)alkoxy, (C1-C3)alkoxy-(C1-C3)alkoxy and N((C1-C3)alkyl)2; and
(ii) a 5 membered N-linked heterocycle containing 1-3 nitrogen atoms, said ring optionally substituted with C(O)NR7R8; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The compound according to claim 10 wherein R1 is a phenyl ring substituted with two substituents, which may be the same or different, each independently selected from fluoro, chloro, methyl, methoxy and cyano; or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The compound according to claim 11 wherein R2 is selected from H, methoxy, ethoxy, 2-methoxyethoxy, dimethylamino, 1,2,3-triazol-2-yl and pyrolidinyl, the latter being optionally substituted by CONH2; or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The compound according to claim 12 wherein R2 is selected from H and methoxy; or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The compound according to claim 13 wherein R3 is H; or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The compound according to claim 14 wherein R1 is a phenyl ring substituted with two substituents, which may be the same or different, each independently selected from fluoro, chloro, methyl, methoxy and cyano; or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The compound according to claim 15 wherein R4 is H, methyl or methoxy; or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The compound according to claim 16 wherein R1 is a phenyl ring substituted with two substituents, which may be the same or different, each independently selected from fluoro, chloro, methyl, methoxy and cyano and R2 is selected from H, methoxy, ethoxy, 2-methoxyethoxy, dimethylamino, 1,2,3-triazol-2-yl and pyrolidinyl, the latter being optionally substituted by CONH2; or a pharmaceutically acceptable salt thereof.

### Claim at position 18

-21. (canceled)

### Claim 22 (depends on 1)

A compound according to claim 1, which is
3-(4-Fluoro-2-methyl-phenyl)-6-[5-methoxymethyl-4-(6-methoxy-pyridin-3-yl)-4H-[1,2,4]triazol-3-yl]-pyridazine; or a pharmaceutically acceptable salt thereof.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim at position 22

-26. (canceled)

### Claim 27 (depends on 1)

A method of treating male sexual dysfunction, female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorder, premature ejaculation, preterm labour, complications in labour, appetite and feeding disorders, benign prostatic hyperplasia, premature birth, dysmenorrhoea, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic hypertension, ocular hypertension, obsessive compulsive disorder or a neuropsychiatric disorder in a mammal, the method comprising administering a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a mammal in need of treatment thereof.

### Claim 28 (depends on 27)

The method according to claim 27 wherein sexual arousal disorder, orgasmic disorder, sexual pain disorder or premature ejaculation is treated.
